Payment overview · 2025
General Payments
$118.45
6 reported records · 4 companies
Healthcare provider profile · identity verified
John F Maddox, MD
Allopathic & Osteopathic Physicians|Family Medicine · ANDALUSIA, AL · NPI 1477575868
Verified facts
What the public records show
CMS Open Payments records show John F Maddox, MD received $118.45 in general payments during 2025 across 6 reported records.
Novo Nordisk Inc accounted for 46.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $54.58 | 46.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $27.40 | 23.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.15 | 17.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.32 | 13.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $118.45 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $54.58 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $54.58 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $27.40 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 568 | 150 |
| Tramadol Hcl | Tramadol Hcl | 523 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 463 | 80 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 403 | 127 |
| Amlodipine Besylate | Amlodipine Besylate | 384 | 103 |
| Lisinopril | Lisinopril | 377 | 93 |
| Losartan Potassium | Losartan Potassium | 309 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 307 | 58 |
| Omeprazole | Omeprazole | 284 | 77 |
| Eliquis | Apixaban | 283 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 281 | 68 |
| Potassium Chloride | Potassium Chloride | 276 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 257 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 249 | 82 |
| Atorvastatin Calcium | Atorvastatin Calcium | 225 | 49 |
| Trazodone Hcl | Trazodone Hcl | 204 | 52 |
| Furosemide | Furosemide | 196 | 56 |
| Simvastatin | Simvastatin | 160 | 39 |
| Clonazepam | Clonazepam | 151 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 150 | 34 |
| Sertraline Hcl | Sertraline Hcl | 148 | 32 |
| Ezetimibe | Ezetimibe | 143 | 41 |
| Metformin Hcl | Metformin Hcl | 139 | 41 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 136 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 133 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 131 | 35 |
| Baclofen | Baclofen | 128 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 128 | 41 |
| Pregabalin | Pregabalin | 127 | 29 |
| Lorazepam | Lorazepam | 125 | 28 |
| Mirtazapine | Mirtazapine | 119 | 21 |
| Donepezil Hcl | Donepezil Hcl | 118 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 115 | 25 |
| Carvedilol | Carvedilol | 110 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 102 | 24 |
| Glipizide Er | Glipizide | 102 | 32 |
| Buspirone Hcl | Buspirone Hcl | 98 | 19 |
| Temazepam | Temazepam | 96 | 13 |
| Alendronate Sodium | Alendronate Sodium | 85 | 23 |
| Allopurinol | Allopurinol | 83 | 22 |
| Famotidine | Famotidine | 83 | 20 |
| Clonidine Hcl | Clonidine Hcl | 80 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 78 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 75 | 14 |
| Jardiance | Empagliflozin | 74 | 16 |
| Montelukast Sodium | Montelukast Sodium | 65 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 64 | 23 |
| Alprazolam | Alprazolam | 62 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 62 | 11 |
| Farxiga | Dapagliflozin Propanediol | 62 | 22 |
| Memantine Hcl | Memantine Hcl | 60 | 11 |
| Prednisone | Prednisone | 60 | 35 |
| Xarelto | Rivaroxaban | 57 | suppressed |
| Finasteride | Finasteride | 56 | 17 |
| Metformin Hcl Er | Metformin Hcl | 56 | 16 |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 55 | 13 |
| Warfarin Sodium | Warfarin Sodium | 54 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 52 | 20 |
| Trulicity | Dulaglutide | 52 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 16 |
| Bumetanide | Bumetanide | 48 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 45 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | 15 |
| Meloxicam | Meloxicam | 44 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 42 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | 11 |
| Atenolol | Atenolol | 41 | 11 |
| Meclizine Hcl | Meclizine Hcl | 41 | 17 |
| Amoxicillin | Amoxicillin | 40 | 22 |
| Diltiazem Hcl | Diltiazem Hcl | 40 | suppressed |
| Entresto | Sacubitril/Valsartan | 40 | suppressed |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Azithromycin | Azithromycin | 39 | 37 |
| Ketoconazole | Ketoconazole | 39 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 38 | 16 |
| Ondansetron Odt | Ondansetron | 37 | 21 |
| Ozempic | Semaglutide | 37 | suppressed |
| Dexamethasone | Dexamethasone | 36 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Primidone | Primidone | 33 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 31 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Risperidone | Risperidone | 30 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 29 | 24 |
| Hydrocortisone | Hydrocortisone | 29 | suppressed |
| Vascepa | Icosapent Ethyl | 28 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 27 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Nexletol | Bempedoic Acid | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Verapamil Sr | Verapamil Hcl | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Galantamine Er | Galantamine Hbr | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 14 |
| Brilinta | Ticagrelor | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Pentoxifylline | Pentoxifylline | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Meropenem | Meropenem | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 18 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 18 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Phenytoin | Phenytoin | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Haloperidol | Haloperidol | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 15 | 15 |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 14 | suppressed |
| Indapamide | Indapamide | 14 | suppressed |
| Novolin R | Insulin Regular, Human | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 12 |
| Tradjenta | Linagliptin | 12 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $118.45 · 6 records | Novo Nordisk Inc | Dexcom G6 Transmitter, MOUNJARO, Ozempic, QULIPTA, Rybelsus, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error